Bioventix Plc · LSE:BVXP
Bioventix — Investor Presentation (October 2019)
15 slides from Bioventix's investor presentation, October 2019
Slide 1: Bioventix Presentation: October 2019
1 Bioventix Presentation: October 2019 ▪Bioventix & antibodies for blood testing ▪Bioventix portfolio of antibodies and their advantages ▪2018/19 final results and comment ▪Research and pipeline development ▪Business continuity ▪Shareholders & the Board ▪Conclusions & outlook
Slide 2: Bioventix (Farnham)
2 Bioventix (Farnham) ▪Fermentation ▪12 FTEs staff in a Bioventix-owned property ▪Purification and testing ▪~£300k investment in a modest expansion and new equipment purchases on-going Q4.2019
Slide 3: Automated Blood Testing
3 Automated Blood Testing ▪Bioventix creates and manufactures sheep monoclonal antibodies (SMAs). Customers incorporate these antibodies in reagent packs for use on automated blood-testing machines antigen antibody ▪Bioventix sells liquid “physical” SMAs and derives royalties from their downstream u
Slide 4: Creating Antibodies
4 Creating Antibodies Myeloma fusion partner ▪Immortal ▪Secretes nothing of use White blood cell (B cell) ▪mortal ▪Secretes a single antibody Polyethylene glycol (PEG) ▪Bioventix’s business is based on the ability of sheep to make better antibodies than mice ▪Better antibodies can facilitate better
Slide 5: Why SMAs? (testosterone)
5 Why SMAs? (testosterone) ▪In 2003, it became clear that testosterone testing for women was inadequate ▪Roche published their prototype assay in 2008 and launched this assay in 2009 ▪It is the Bioventix antibody that made this possible
Slide 6: Why SMAs? (troponin)
6 Why SMAs? (troponin) ▪Troponin is a component of heart muscle that ▪Magnetic particle ▪Fluorescent label leaks out after a heart attack ▪A new improved Siemens assay for troponin (ie to help diagnose chest pain) which uses Bioventix antibodies was released in ex-US markets in May 2017 and in the U
Slide 7: Key Financials
7 Key Financials £ (‘000) Year to year to Finncap 30.6.18 30.6.19 2019/20 Sales 7,979 9,290 10,100 (excluding £772k back-royalty in 2017/18) P/(L) before tax 6,094 6,965 7,660 (excluding £772k back-royalty in 2018/18) P/(L) after tax 5,038 5,861 6,360 (excluding £772k back-royalty in 2017/18) P/(L)
Slide 8: Thyroid, Heart failure, Fertility, Chest pain
8 Thyroid Heart failure Fertility Chest pain
Slide 9: Customer and market commentary
9 ▪Market flattening & many ▪Variable performance due to a individual customer revenue number of different parameters ▪Roll-out of high streams flatter sensitivity assays slowly ▪Overall growth slightly better gathering pace ▪Diazyme (San Diego) and than the 5-10% generally Boditech (Korea) doing we
Slide 10: Pipeline Development 2019
10 Pipeline Development 2019 high Secretoneurin/SN (CardiNor) Pollution biomonitoring Amyloid (Pre-Diagnostics) ← Increasing potential value Cardiac MyC (King’s) medium Biotin (blocking Abs) virus (contract) T4 (thyroxine) Low thyroglobulin (contract) Cancer Vitamin (contract) (contract) Low Medium
Slide 11: Pollution and Bio-Monitoring
11 Pollution and Bio-Monitoring ▪Fixed and portable devices are able to monitor NOx & PM2.5 particles derived from combustion processes that pollute air ▪The objective of the pollution biomonitoring project is to create a lab-based “ELISA” urine test that would give a measurement of actual individua
Slide 12: Business Dynamics
12 Business Dynamics +1 year Prototype test 2-4 years Old test = 3-5 years total ▪Bioventix takes about 1 year to make antibodies ▪Customers take 2-4 years to: formulate a prototype test; conduct field trials; submit data to regulatory authorities; obtain marketing approval ▪This is an impediment to
Slide 13: Selected Shareholder Base
13 Selected Shareholder Base Institution Shares % (1000s) Sanford DeLand (Castlefield) 985 19.2 Canaccord (Hargreave Hale) 515 10.0 Peter Harrison 428 8.3 Liontrust 395 7.7 Gresham House (Livingbridge) 356 6.9 Jupiter Asset Management 200 3.9 Wasatch Advisors, Inc (Salt Lake City) 151 3.0 Miton Grou
Slide 14: Bioventix Directors
14 Bioventix Directors ▪Peter Harrison, CEO ▪Ian Nicholson, Chairman ▪>30 years experience of ▪>30 years experience of antibody technology at commercial development Celltech, KS Biomedix & within biotechnology Bioventix including Amersham, Celltech, Chroma, Clinigen & Consort Medical ▪Treena Turner,
Slide 15: Conclusions and Outlook
15 Conclusions and Outlook ▪ 2018/19: Another good year of financial results and research pipeline expansion ▪ 2020-2025: growth linked to initial troponin roll-out and growth in the troponin market through additional troponin applications ▪ New products emerging from the company’s R&D pipeline shou